The agenda can be found at https://n2canada.ca/wp-content/uploads/2020/01/AGENDA-V5.0.pdf
DIGITAL ATTENDANCE COST
N2 is live streamlining their N2 annual meeting! If you are unable to attend but would like to view the 2-day meeting digitally there is now an option to do so.
- Member registration is $35.00 plus HST
- Non-Member registration is $70.00 plus HST
- Member registration is $75.00 plus HST
- Non-Member registration is $800.00 plus HST (Non-member conference registration fee will be applied to the cost of membership taken out before the end of the conference).
CADTH Lecture The Canadian Partnership for Tomorrow Project | Conférences de l’ACMTS Le Projet de partenariat canadien Espoir pour demain [register for the 16-Jan-2020, livestream]
The Canadian Partnership for Tomorrow Project: Canada’s Population Health Cohort
Speaker: Dr. Philip Awadalla, PhD, National Scientific Director for the CPTP, Director of Computational Biology, and the Executive Scientific Director of the Ontario Health Study at the Ontario Institute for Cancer Research, and Professor of Population and Medical Genomics at the University of Toronto.
The Canadian Partnership for Tomorrow Project (CPTP) is Canada’s largest population cohort that allows researchers to explore how genetics, environment, lifestyle, and behaviour interact and contribute to the development of cancer and other chronic diseases. The national cohort brings together six regional cohorts: BC Generations Project, Alberta’s Tomorrow Project, the Manitoba Tomorrow Project, Ontario Health Study, CARTaGENE, and the Atlantic Partnership for Tomorrow’s Health. These cohorts have cumulatively enrolled more than 320,000 Canadians who are older than 30. Baseline data has been harmonized across the country, creating a pan-Canadian resource of more than 1,600 measures of participant health and lifestyle factors, including, but not limited to: personal and family disease histories, medication use, sex and reproductive health, diet and nutrition, sun exposure, and alcohol and tobacco use. More than 150,000 participants have provided biological samples, measures of glycated hemoglobin, complete blood counts, and physical measurements (e.g., anthropometrics, blood pressure, and body fat percentage). A significant benefit of CPTP is that all participants have provided consent to link their information to regional administrative health databases. This unique feature enables the longitudinal analyses of changes in clinical outcomes carried out in parallel with the analysis of biologics and deeply characterized health and lifestyle information. Alongside a wealth of cardiometabolic phenotypes, CPTP is well positioned to support studies focused on how genetics and the environment interact to drive cancer, cardiovascular disease, diabetes onset, and other outcomes in the Canadian context.
Date: Thursday, January 16, 2020, in person or via live stream
Time: 1:30 p.m. to 2:45 p.m. EST
Location: Dow’s Lake Court Conference Centre, 865 Carling Avenue, Ottawa, Ontario
Live stream: Details on registration
There is no fee to participate, but you must register by Wednesday January 15, 2020, to attend or livestream the event.
Feel free to distribute this invitation within your networks. We sincerely hope you and your colleagues can join us. If you have any questions about the lecture or how to register, please contact us at email@example.com.
Le Projet de partenariat Canadien Espoir pour demain : la santé de la population au Canada
Conférencière : Le Dr Philip Awadalla est le directeur scientifique national du Projet de partenariat canadien Espoir pour demain, le directeur de la bio-informatique et le directeur général scientifique de l’Étude sur la santé Ontario à l’Institut ontarien de recherche sur le cancer. De plus, il enseigne la génomique des populations et la génomique médicale à l’Université de Toronto et il dirige le Centre canadien d’intégration des données de Génome Canada. Il est titulaire d’un doctorat en génétique des populations et en génétique statistique de l’Université d’Édimbourg. Il poursuit des études postdoctorales grâce à des bourses d’études (NSERC, Killam, Wellcome Trust), puis il occupe un poste de professeur aux universités de la Caroline du Nord et de Montréal. Pendant un temps, il est le directeur scientifique de CARTaGENE et fait partie du groupe d’analyse du projet 1 000 Génomes et du Pan-Cancer Analysis of Whole Genomes. Ses principaux projets sont axés sur la génomique du vieillissement, les maladies hématologiques et le cancer. D’autres portent sur l’estimation des taux de mutation et de recombinaison, la modélisation et la génétique, et les risques environnementaux de maladies infectieuses en Afrique.
Le Projet de partenariat canadien Espoir pour demain (PPCED) représente la plus vaste plateforme de recherche sur la santé de la population au Canada; dans le cadre de ce projet, des chercheurs étudient l’influence et l’interaction de facteurs génétiques et environnementaux, du mode de vie et du comportement dans l’apparition du cancer et d’autres maladies chroniques. D’importance cruciale, le PPCED permettra de mieux comprendre l’interaction entre des facteurs individuels comme le style de vie, le comportement et la génétique et l’environnement, et leur influence dans l’apparition du cancer et d’autres maladies. La cohorte nationale regroupe six cohortes régionales : le projet BC Generations, le projet Tomorrow de l’Alberta, le projet Tomorrow du Manitoba, l’Étude sur la santé Ontario, le projet CARTaGENE et le projet LA VOIE Atlantique; elle compte plus de 320 000 Canadiennes et Canadiens de plus de 30 ans. Les données de base recueillies au pays ont été harmonisées et elles forment une ressource pancanadienne portant sur plus de 1 600 paramètres mesurés sur la santé et le mode de vie, dont les antécédents médicaux personnels et familiaux, les médicaments utilisés, le sexe et la santé reproductive, le régime alimentaire et la nutrition, l’exposition au soleil, la consommation d’alcool et le tabagisme. Plus de 150 000 participants ont offert des échantillons biologiques, des mesures du taux d’hémoglobine glyquée, des hémogrammes et des mesures physiques (p. ex., caractéristiques anthropométriques, pression artérielle, pourcentage de gras corporel). L’une des retombées importantes du projet est que tous les participants ont consenti à ce que leurs renseignements personnels soient versés dans des bases de données administratives régionales du secteur de la santé. Ainsi, il est possible d’analyser dans une perspective longitudinale l’évolution des résultats cliniques en parallèle avec l’analyse des échantillons biologiques et de l’information individuelle étoffée sur la santé et le mode de vie. Corpus d’une vaste gamme de phénotypes cardiométaboliques, le PPCED constitue également une mine de renseignements permettant l’étude de l’interaction entre les facteurs génétiques et environnementaux dans l’apparition du cancer, des maladies cardiovasculaires, du diabète et d’autres problèmes de santé au Canada.
Date : Jeudi 16 janvier 2020
Heure : 13 h 30 à 14 h 45
Lieu : Salle du conseil, Dow’s Lake Court, ou en diffusion continue en direct
La conférence est offerte gratuitement, mais il faut s’y inscrire au plus tard mercredi 16 janvier 2020.
Inscrivez-vous dès maintenant: https://cadth.ca/fr/evenements/le-projet-de-partenariat-canadien-espoir-pour-demain-la-sante-de-la-population-au-canada
N’hésitez pas à partager cette invitation au sein de votre réseau. Nous espérons sincèrement que vous-même et certains de vos collègues pourrez vous joindre à nous lors de cette conférence. Si vous avez des questions à ce sujet ou encore pour savoir comment vous inscrire, n’hésitez pas à nous contacter à firstname.lastname@example.org.
SEMINAR: Statistical Models vs Machine Learning in Health Research [May 2nd; live streaming available]
The Dalla Lana School of Public Health at the University of Toronto will be hosting a public lecture by Prof. Frank E. Harrell Jr. on Thursday May 2, 2019 from 11am to 12 noon, 155 College St. Room HS574. The title of the talk is “Musings on Statistical Models vs Machine Learning in Health Research”.
Registration for the event is required. The talk will also be available to access remotely by live streaming. If you register to participate for the event remotely an access link will be forwarded to you closer to the event.
The link to the registration site is
Health researchers and practicing clinicians are with increasing frequency hearing about machine learning (ML) and artificial intelligence applications. They, along with many statisticians, are unsure of when to use traditional statistical models (SM) as opposed to ML to solve analytical problems related to diagnosis, prognosis, treatment selection, and health outcomes. And many advocates of ML do not know enough about SM to be able to appropriately compare performance of SM and ML. ML experts are particularly prone to not grasp the impact of the choice of measures of predictive performance. In this talk I attempt to define what makes ML distinct from SM, and to define the characteristics of applications for which ML is likely to offer advantages over SM, and vice-versa. The talk will also touch on the vast difference between prediction and classification and how this leads to many misunderstandings in the ML world. Other topics to be covered include the minimum sample size needed for ML, and problems ML algorithms have with absolute predictive accuracy (calibration). Presented by Professor Frank E. Harrell, Department of Biostatistics, Vanderbilt University.
About the Instructor:
- Professor and founding Chair of the Department of Biostatistics, Vanderbilt University School of Medicine, Nashville TN USA
- PhD in Biostatistics from U. North Carolina
- Extensive work in biomedical and pharmaceutical research
- ASA Fellow and winner of the ASA WJ Dixon Award for Excellence in Statistical Consulting in 2014
- Active on stats.stackexchange.com – see my posts here
- Written several R packages including Hmisc and rms
- Used R intensively since 1999 and am a member of the R Foundation
- Author of Regression Modeling Strategies, 2nd Edition
- Statistical knowledge outside the areas of regression modeling strategies and Bayes is in BBR
- Expert Statistical Advisor to the Office of Biostatistics, Center for Drug Evaluation and Research, FDA
The Canadian Institutes of Health Research Institute of Cancer Research (ICR) and Institute of Neurosciences, Mental Health and Addiction (INMHA), in partnership with the Canadian Cancer Society, will support Research investigating the benefits and/or harms related to therapeutic use of cannabis in people living with cancer.
See CIHR grant page HERE
The Cannabis Research in Priority Areas Team Grants is expected to:
- •Generate new scientific knowledge that will advance our understanding of the potential benefits and/or harms of cannabis and/or cannabis use, and impact policies and programs in this area
- Encourage interdisciplinary collaborations, including from across health research and from domains outside of health research, and the sharing of data and resources
- Enhancing capacity development and training in cannabis research
- Connect to existing knowledge translation efforts across Canada, for example through MHCC or the Canadian Centre on Substance Use and Addiction (CCSA)
The maximum amount per grant is $300,000 per year for up to 5 years for a total of $1.5 million, per grant. $1.5 million is available to fund an application relevant to the Cancer Pool (sponsored by the Canadian Cancer Society, ICR, and INMHA).
LOI due date: May 15, 2019
LOI notice of decision: July 15, 2019
Full application deadline: October 8, 2019
Funding start date: January 1, 2020
All applications must be submitted through CIHR’s ResearchNet. For more information view the funding opportunity details on the CIHR website.
CIHR will be hosting webinar(s) to review with participants the requirements of this funding opportunity and to answer questions. To find out more information and to register, visit the Webinars page.
The goal of the CCS/CIHR Cancer Survivorship Team Grant program is to improve the health outcomes for cancer survivors of all ages (pediatric, adolescent, young adult and adult) from the time of their cancer diagnosis until the time of their death or entry into palliative care. This program is not intended to focus on improving end-of-life care.
The intent of this funding opportunity is to support new intervention research designed to mitigate the challenges experienced along the survivorship journey, as well as the evaluation and validation of existing interventions to assess their potential for implementation as best practices.
The program goal will be achieved through the support of a network of multidisciplinary teams, each led by a nominated Principal Investigator and at least 2 co-Principal and/or co- Investigators, one of whom must be within their first five years as an independent researcher, drawn from at least 3 different regions of Canada (Atlantic Provinces, Central Canada, Prairie Provinces, West Coast, Northern Territories). Survivors and caregivers are expected to be engaged as full and active members of research teams.
Teams may request up to $500,000 per year for a maximum of $2,500,000 over a five-year period. Grants will be non-renewable. As the total budget for this competition is $10 million, it is anticipated that at least 4 teams will be funded in this competition. The engagement of additional partners may increase this number.
Registration due date: May 29, 2019
Relevance review results: mid-June, 2019
Full application deadline: September 10, 2019
Results announcement : November 2019
Anticipated start date: December 1, 2019
All applications must be submitted through the online application system (EGrAMS) by 5p.m. EST on the deadline date. Submissions will not be accepted beyond these times.
A Webinar is planned to explain the application process and overall objectives of the call. Applicants can register by sending an email at email@example.com. Details for the April 8th, 2019 (@1pm EST) webinar will be provided in advance to interested applicants.
Please confirm your participation in this free webinar by April 1st, and register online, by visiting http://www.pogo.ca/education/synoptic-reporting/
On April 3, 2019, POGO is pleased to present an important professional development educational event in partnership with the Canadian Association of Pathologists (CAP-ACP) and the Canadian Partnership Against Cancer (CPAC).
The webinar “Synoptic Pathology Reporting for Pediatric Patients with Hepatoblastoma” will provide expert advice for advancing pediatric oncology through optimal pathology investigation, moving toward standardized reporting, and incremental clarity of clinical implications.
Date: Wednesday, April 3, 2019
Time: 1:00 – 2:30 p.m. (60 minutes presentation; 30 minutes Q & A)
Speaker: Dr. Dina El Demellawy, MD, PhD, FRCPC
Pediatric and Perinatal Pathologist, Children’s Hospital of Eastern Ontario (CHEO) Associate Professor, Department of Pathology and Laboratory Medicine Faculty of Medicine, University of Ottawa
Audience: Pathologists, Pathology Fellows and Residents;
Pediatric Oncologists, Surgeons, Radiation Oncologists; Clinical Research Associates (CRAs).
- To review the CAP protocols related to Hepatoblastoma and its use by pathologists specializing in pediatric oncology.
- To understand changes in the latest revision of the CAP cancer protocols and electronic cancer checklists.
Participation details: Please confirm your participation in this free webinar by April 1st, by visiting http://www.pogo.ca/education/synoptic-reporting/ to register online.
For questions about registration, please contact Clara Jordan at firstname.lastname@example.org@pogo.ca or 416-592-1232 ext. 237. Webinar login details will be provided in advance of the event.
Recording of LLSC WEBCAST now available – Children & Teens with Cancer: Challenges at School after Treatment
Speaker: Ann Klinck, M.A.Sc., C. Psych. Assoc., School Liaison, Pediatric Cancer School Support Program, Children’s Hospital, London Health Sciences Centre, Ontario
This training is useful for those who support children and teens during and after the cancer experience including parents, relatives, teachers, school support staff and nurses. The recording of this webcast can found on our Website at: www.llscanada.org/events/children-teens-with-cancer-challenges-at-school-after-treatment?src1=22346&src2=
CAR T-cell therapy webinar by Jim Whitlock recorded and available online (Canadian Cancer Survivor Network)
On June 1 Dr. Jim Whitlock (The Hospital for Sick Children) presented a webinar on CAR T-cell therapy. This webinar was part of the Canadian Cancer Survivor Network seminar series and the recording is available online.
C17 Education webinar series: Cognitive and Neuroimaging Outcomes in Cognitive/Brain Rehabilitation Approaches by Donald Mabbott [30-May-2018 12pm MT]
The next C17 Educational Presentation will be held on: Wednesday, May 30th at 12:00 – 13:00 (MST). Webinar details have been set to the sites – contact C17 for more information.
Presenter: Donald J. Mabbott, Ph.D., C. Psych., ABPP (Program Head, Neurosciences and Mental Health, Hospital for Sick Children)
Presentation Title: Cognitive and Neuroimaging Outcomes in Cognitive/Brain Rehabilitation Approaches
- Explore what quantitative neuro-imaging has allowed us to understand
- Discuss how we have used different neuro-imaging approaches to characterize white matter structure and neural function in paediatric brain tumour survivors
- Consider how the tissue properties of white matter structure may affect cognition in these children
- Learn how white matter plasticity can be harnessed for brain repair and cognitive restoration in this vulnerable population of patients
CYP-C Research Champion Webinars: “Epidemiology of thrombo-embolism in children with cancer: a population-based study” (AKA an example of CYP-C data in use) 23-Mar-2018 12 EST
Topic: Epidemiology of thrombo-embolism in children with cancer: a population-based study
Presenter: Marie-Claude Pelland-Marcotte
Date: Friday, March 23, 2018
Time: 12:00 pm, Eastern Standard Time
For webinar information, contact Randy Barber in the C17 Office (randy.barber@AHS.ca)
This month’s webinar will be a change of pace, with results presented from a CYP-C data use application by Marie-Claude Pelland-Marcotte. Marie-Claude trained in Pediatric Hematology-Oncology from 2014 to 2017 in Toronto, at the Hospital for Sick Children and is currently doing a post-doctoral fellowship in Pediatric Hemostasis and Thrombosis. She is also undertaking a Master’s degree in Health Services Research at the University of Toronto. She will start a position as a staff hematologist in 2019 at the Centre Hospitalier Universitaire de Québec (Université Laval).
Past webinars are available on the C17 website under committees>CYP-C and are linked below.
Research Champion Webinars (2018)
The objective of this webinar series is to provide members of the Canadian pediatric cancer community a broad understanding of how to access and utilize the Cancer in Young People in Canada data for research purposes. This series will include an overview of how to (1) develop an appropriate research question, (2) complete the data access process and (3) perform basic data manipulation and analysis using SAS and Microsoft Access. The webinars will be delivered once per month over the 2018 calendar year. We look forward to your participation!
CONFIRMED (2018; times are noon EST unless stated)
Institutional Reports (Feb 23)
Flat File Reports
Data Manipulation in Access
Potential Publication Collaborations
|1. Childhood cancer incidence in Canada: temporal, regional and deprivation-related patterns|
|2. Socioeconomic status and childhood cancer incidence|
|3. Association between socioeconomic characteristics and childhood cancer survival|
|4. Diagnostic and treatment intervals and childhood cancer survival: economic and distance dimensions|
|5. Incidence of relapse of childhood cancer (recurrence of the primary malignancy)|
|6. Health status/complications in survival of childhood cancer during 5 year follow-up|
|7. Subsequent malignancy rates of childhood cancer|
|8. Incidence and survival of childhood cancer in Canada**|
|9. Diagnostic and treatment intervals for pediatric cancer care in Canada|
|10. Completeness of case ascertainment of non-malignant CNS tumors in CYP-C|
|11. Access to care and survival of aboriginal children**|
|12. Spatial analysis of childhood cancer incidence**|
|13. Prognostic impact of demographic, histologic and therapeutic factors on childhood cancer survival in Canada|
|14. Childhood brain cancers: incidence and survival**|
|15. Health adjusted life expectancy (HALE) of childhood cancer|
|16. Obesity (BMI) and childhood cancer risk|
**There are ongoing approved CYP-C projects in this area